Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of pembrolizumab in relapsed or refractory classical Hodgkin lymphoma
2014-004482-24Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in Hodgkin lymphoma (HL) (3 cohorts), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Overall response rate. Started Apr 2015; status: completed.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2014-004482-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004482-24.